GlassScriptPhysician profile
Joy D Cornelius
NPI 1942283635
$23,736.01
in general payments reported to CMS, 2019-2025
25 companies · $3,954 in 2025
The $3,954 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,590 · 2022: $3,335 · 2023: $3,687 · 2024: $3,170 · 2025: $3,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $66.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,744.41 |
| Education | $66.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,679.37 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,406.31 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $1,286.62 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,128.64 | 2021-2025 | Caplyta |
| Alkermes, INC. | $931.76 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $884.80 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $829.07 | 2021-2025 | Ingrezza |
| Corium, LLC | $793.00 | 2021-2025 | Azstarys |
| Lundbeck LLC | $772.40 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $681.74 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $617.00 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $515.65 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $476.05 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $365.90 | 2024-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $212.08 | 2022-2024 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $191.92 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Collegium Pharmaceutical, INC. | $184.47 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $177.48 | 2022-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $164.01 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $125.06 | 2024-2025 | Cobenfy |
| Biogen, INC. | $108.55 | 2024-2025 | Zurzuvae |
| Bausch Health US, LLC | $95.05 | 2021-2023 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $63.66 | 2024-2025 | Loreev Xr |
| Eisai INC. | $26.29 | 2021 | |
| Noven Therapeutics, LLC | $19.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Cornelius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.